Cargando…
Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus
Hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus have a median survival time of only about 4 months. We therefore compared the safety and efficacy of endovascular brachytherapy (EVBT) and sequential three-dimensional conformal radiotherapy (3-DCRT). From a cohort of 176 p...
Autores principales: | Yu, Tian-Zhu, Zhang, Wen, Liu, Qing-Xin, Li, Wen-Hui, Ma, Jing-Qin, Zhang, Zi-Han, Yang, Min-Jie, Wang, Jian-Hua, Chen, Bing, Zeng, Shao-Chong, Luo, Jian-Jun, Liu, Ling-Xiao, Yan, Zhi-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355329/ https://www.ncbi.nlm.nih.gov/pubmed/28076848 http://dx.doi.org/10.18632/oncotarget.14520 |
Ejemplares similares
-
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
por: Zhang, Zi-Han, et al.
Publicado: (2017) -
Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus
por: Zheng, Ninggang, et al.
Publicado: (2016) -
Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
por: Yang, Biao, et al.
Publicado: (2016) -
Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis
por: Xue, Tong-Chun, et al.
Publicado: (2013) -
Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis
por: Zhang, Zi-Han, et al.
Publicado: (2023)